Literature DB >> 17654509

Hemostatic and thrombotic markers in patients with hemoglobin E/beta-thalassemia disease.

Pantep Angchaisuksiri1, Vichai Atichartakarn, Katcharin Aryurachai, Napaporn Archararit, Suporn Chuncharunee, Arjit Tiraganjana, Sasivimol Rattanasiri.   

Abstract

Increased frequency of thrombosis has been observed in patients with hemoglobin E/beta-thalassemia (Hb E/beta-thal) disease, particularly those who have previously been splenectomized. We compared various hemostatic and thrombotic markers in blood from 15 Hb E/beta-thal patients who were not splenectomized (NS), 15 who had been splenectomized (S), and 15 normal controls (NC). Levels of plasma thrombin-antithrombin, beta2 thromboglobulin, C-reactive protein, tissue plasminogen activator antigen were significantly higher in the S group than in either the NS or the NC groups, and levels of prothrombin fragment 1.2 were significantly higher in the S than in the NC group. Levels of plasminogen activator inhibitor-1 antigen were significantly higher in the S than in the NS group. Levels of protein C, protein S, antithrombin, and fibrinogen were significantly lower in the S and NS groups than in the NC group. Plasma lipoprotein(a) levels in the S and NS groups were not statistically different from NC. Our findings indicated that there is evidence of chronic low-grade coagulation and platelet activation, chronic low-grade inflammation, endothelial cell injury, impaired fibrinolysis, and decreased naturally occurring anticoagulants in splenectomized Hb E/beta-thal patients. These changes may account for the increased risk of thrombosis in these patients. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17654509     DOI: 10.1002/ajh.20945

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

1.  Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.

Authors:  Aruna Chhikara; Sunita Sharma; Jagdish Chandra; Anita Nangia
Journal:  Indian J Pediatr       Date:  2016-08-03       Impact factor: 1.967

2.  PAI-1 Study in Thalassemia Major Patients Receiving Multiple Blood Transfusion.

Authors:  Ashwini Kumar; H S Batra; Mithu Banerjee; S Bandyopadhyay; T K Saha; Pratibha Misra; Vivek Ambade
Journal:  Indian J Clin Biochem       Date:  2016-10-13

3.  Impact of β-thalassemia trait carrier state on cardiovascular risk factors and metabolic profile in patients with newly diagnosed hypertension.

Authors:  A I Triantafyllou; G P Vyssoulis; E A Karpanou; P L Karkalousos; E A Triantafyllou; A Aessopos; D T Farmakis
Journal:  J Hum Hypertens       Date:  2013-10-24       Impact factor: 3.012

Review 4.  Leg Ulcers: A Report in Patients with Hemoglobin E Beta Thalassemia and Review of the Literature in Severe Beta Thalassemia.

Authors:  Vikita Mehta; Abirami Kirubarajan; Amir Sabouhanian; Sanasi M Jayawardena; Priya Chandrakumaran; Nila Thangavelu; Refai Cader; Sachith Mettananda; Dayananda Bandara; Shawn Khan; David J Weatherall; Angela Allen; Anuja P Premawardhena; Nancy F Olivieri
Journal:  Acta Haematol       Date:  2021-11-09       Impact factor: 3.068

5.  Hydroxycarbamide-induced changes in E/beta thalassemia red blood cells.

Authors:  Sylvia T Singer; Elliott P Vichinsky; Sandra Larkin; Nancy Olivieri; Nancy Sweeters; Frans A Kuypers
Journal:  Am J Hematol       Date:  2008-11       Impact factor: 10.047

6.  Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy.

Authors:  Sylvia T Singer; Frans Kuypers; Jeffery Fineman; Ginny Gildengorin; Sandra Larkin; Nancy Sweeters; Howard Rosenfeld; Gregory Kurio; Annie Higa; Michael Jeng; James Huang; Elliott P Vichinsky
Journal:  Ann Hematol       Date:  2014-02-28       Impact factor: 3.673

Review 7.  HbE/β-Thalassemia and Oxidative Stress: The Key to Pathophysiological Mechanisms and Novel Therapeutics.

Authors:  Rhoda Elison Hirsch; Nathawut Sibmooh; Suthat Fucharoen; Joel M Friedman
Journal:  Antioxid Redox Signal       Date:  2016-11-28       Impact factor: 8.401

8.  [Changes of plasma TF and TFPI in 20 cases thalassemia patients before and after splenectomy].

Authors:  D H Deng; N Sun; Y Long; P Cheng; Y R Lai
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

9.  Microparticles from β-thalassaemia/HbE patients induce endothelial cell dysfunction.

Authors:  Wasinee Kheansaard; Kunwadee Phongpao; Kittiphong Paiboonsukwong; Kovit Pattanapanyasat; Pornthip Chaichompoo; Saovaros Svasti
Journal:  Sci Rep       Date:  2018-08-29       Impact factor: 4.379

10.  Protein C and Anti-Thrombin-III Deficiency in Children With Beta-Thalassemia.

Authors:  Suzy Abd El Mabood; Doaa Moawad Fahmy; Ahmed Akef; Shadia El Sallab
Journal:  J Hematol       Date:  2018-05-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.